.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,328,133

« Back to Dashboard

Details for Patent: 9,328,133

Title:Ferric organic compounds, uses thereof and methods of making same
Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.
Inventor(s): Kwok; David W. K. (Vancouver, CA), Stoynov; Nikolay Mintchev (Vancouver, CA)
Assignee: Panion & BF Biotech Inc. (TW)
Filing Date:Sep 30, 2014
Application Number:14/502,774
Claims:1. Ferric citrate having an intrinsic dissolution rate of 1.88-4.0 mg/cm.sup.2/min.

2. The ferric citrate of claim 1, wherein the intrinsic dissolution rate is measured by USP (United States Pharmacopeia) intrinsic dissolution assay in water.

3. The ferric citrate of claim 1, wherein the intrinsic dissolution rate is selected from 1.88 mg/cm.sup.2/min, 2.68 mg/cm.sup.2/min, 3.82 mg/cm.sup.2/min and 4.00 mg/cm.sup.2/min.

4. The ferric citrate of claim 1, having the formula C.sub.6H.sub.5O.sub.7Fe.

5. The ferric citrate of claim 1, which is in an orally administrable form.

6. The ferric citrate of claim 5, wherein the orally administrable form is selected from a tablet, a powder, a suspension, an emulsion, a capsule, a granule, a troche, a pill, a liquid, a spirit and a syrup.

7. The ferric citrate of claim 5, wherein the orally administrable form is a tablet.

8. A method of treating hyperphosphatemia comprising administering ferric citrate having an intrinsic dissolution rate of 1.88-4.0 mg/cm.sup.2/min to a patient in need of such treatment.

9. A method of treating metabolic acidosis comprising administering ferric citrate having an intrinsic dissolution rate of 1.88-4.0 mg/cm.sup.2/min to a patient in need of such treatment.

10. A pharmaceutical composition comprising ferric citrate having an intrinsic dissolution rate of 1.88-4.0 mg/cm.sup.2/min and a suitable carrier.

11. The pharmaceutical composition of claim 10, wherein the intrinsic dissolution rate is measured by USP (United States Pharmacopeia) intrinsic dissolution assay in water.

12. The pharmaceutical composition of claim 10, wherein the intrinsic dissolution rate is selected from 1.88 mg/cm.sup.2/min, 2.68 mg/cm.sup.2/min, 3.82 mg/cm.sup.2/min and 4.00 mg/cm.sup.2/min.

13. The pharmaceutical composition of claim 10, wherein the ferric citrate has the formula C.sub.6H.sub.5O.sub.7Fe.

14. The pharmaceutical composition of claim 10, wherein the composition is in an orally administrable form.

15. The pharmaceutical composition of claim 14, wherein the orally administrable form is selected from a tablet, a powder, a suspension, an emulsion, a capsule, a granule, a troche, a pill, a liquid, a spirit and a syrup.

16. The pharmaceutical composition of claim 14, wherein the orally administrable form is a tablet.

17. A method of treating hyperphosphatemia comprising administering a pharmaceutical composition comprising ferric citrate having an intrinsic dissolution rate of 1.88-4.0 mg/cm.sup.2/min and a suitable carrier to a person in need of such treatment.

18. A method of treating metabolic acidosis comprising administering a pharmaceutical composition comprising ferric citrate having an intrinsic dissolution rate of 1.88-4.0 mg/cm.sup.2/min and a suitable carrier to a person in need of such treatment.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc